Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Objective Interferon α (IFNα) therapy leads to hematological remissions and a reduction of the JAK2V617F allele burden in patients with polycythemia vera (PV). In this study, the cellular target by which IFNα affects hematopoiesis in PV patients was evaluated. Materials and Methods CD34+ cells were isolated from normal bone marrow and the peripheral blood of patients with PV and were treated in vitro with each of the three commercially available forms of IFNα: IFNα 2b, pegylated IFN α 2a (Peg-IFNα 2a) and pegylated IFN α 2b (Peg-IFNα 2b). Results Each form of IFNα was equally potent in suppressing hematopoietic colony formation by normal CD34+ cells, but Peg-IFNα 2a and IFNα 2b were more effective than Peg-IFNα 2b in inhibiting BFU-E derived colony formation by PV CD34+ cells. In addition, exposure of PV CD34+ cells to equal doses of Peg-IFNα 2a and IFNα 2b resulted in a 38–40% reduction in the proportion of JAK2V617F-positive hematopoietic progenitor cells (HPC), while equivalent doses of Peg-IFNα 2b did not reduce the number of malignant HPC. Further studies explored the mechanism by which IFNα induced PV HPC growth inhibition. Treatment of Peg-IFNα 2a increased the rate of apoptosis of PV CD34+ cells and the phosphorylation/activation of p38 MAPK in PV CD34+ cells, while the p38-specific inhibitor SB203580 reversed the growth inhibition and apoptosis induced by Peg-IFNα 2a. Conclusion These data suggest that low doses of IFNα selectively and directly suppress PV JAK2V617F HPC and that these agents act through the p38 MAP kinase pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
IFNα activates dormant haematopoietic stem cells in vivo
Essers, M. A. G., Offner, S., Blanco-Bose, W. E., Waibler, Z., Kalinke, U., Duchosal, M. A., & Trumpp, A. (2009) · Nature · doi:10.1038/nature07815 · Cited by 1,368 · cited 1×
“Recently, however, IFNa has been shown in a murine system to also be capable of promoting cycling of quiescent hematopoietic stem cells, indicating that IFNa might differentially affect cells belonging to different stages along the hematopoietic cellular hierarchy [37,38].”
Modification of hematopoietic stem cell fate by 5aza 2′deoxycytidine and trichostatin A.
Milhem, M., Mahmud, N., Lavelle, D., Araki, H., DeSimone, J., Saunthararajah, Y., & Hoffman, R. (2004) · Blood · doi:10.1182/blood-2003-07-2431 · Cited by 195 · cited 1×
“The increased number of assayable HPC with wild-type JAK2, which appear following treatment with Peg-IFNa 2a is likely due to a pool of such HPC, which persist after elimination of the JAK2V617F þ HPC [48].”
Self-citationAlsayed, Y., Uddin, S., Mahmud, N., Lekmine, F., Kalvakolanu, D. V., Minucci, S., Bokoch, G., & Platanias, L. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007431200 · Cited by 161
Cited by
Antitumour actions of interferons: implications for cancer therapy
Parker, B. S., Rautela, J., & Hertzog, P. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.14 · Cited by 907
MDM2 inhibition: an important step forward in cancer therapy
Konopleva, M., Martinelli, G., Daver, N., Papayannidis, C., Wei, A., Higgins, B., Ott, M., Mascarenhas, J., & Andreeff, M. (2020) · Leukemia · doi:10.1038/s41375-020-0949-z · Cited by 376
Self-citationKoschmieder, S., Mughal, T. I., Hasselbalch, H. C., Barosi, G., Valent, P., Kiladjian, J.-J., Jeryczynski, G., Gisslinger, H., Jutzi, J. S., Pahl, H. L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.12 · Cited by 161
Central Role of ULK1 in Type I Interferon Signaling
Saleiro, D., Mehrotra, S., Kroczynska, B., Beauchamp, E. M., Lisowski, P., Majchrzak-Kita, B., Bhagat, T. D., Stein, B. L., McMahon, B., Altman, J. K., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.03.056 · Cited by 74
Interferons: role in cancer therapy
Abdolvahab, M. H., Darvishi, B., Zarei, M., Majidzadeh-A, K., & Farahmand, L. (2020) · Immunotherapy · doi:10.2217/imt-2019-0217 · Cited by 50
Metadata
- Authors
- Lu, M., Zhang, W., Li, Y., Berenzon, D., Wang, X., Wang, J., Mascarenhas, J., Xu, M., & Hoffman, R.
- Venue
- Experimental Hematology
- Publisher
- Elsevier BV
- Published
- 2010-06
- Volume
- 38
- Issue
- 6
- Pages
- 472-480
- ISSN
- 0301-472X (ISSN-L)
- OpenAlex
- W2097922857
- Cited by
- 80
- References
- 4
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. https://app.cochat.ai/papers/10.1016/j.exphem.2010.03.005
- The paper
- Lu, M., Zhang, W., Li, Y., Berenzon, D., Wang, X., Wang, J., Mascarenhas, J., Xu, M., & Hoffman, R. (2010). Interferon-α targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway. Experimental Hematology. https://doi.org/10.1016/j.exphem.2010.03.005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.